Go Pro
→ Not oil. Not solar. Bigger. (From Behind the Markets) (Ad)tc pixel Free BGM Stock Alerts

BGM Group (BGM) Competitors

BGM Group logo
$0.28 -0.01 (-2.38%)
Closing price 03:58 PM Eastern
Extended Trading
$0.28 0.00 (0.00%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BGM vs. AARD, CUE, SPRO, OGI, and ENGN

Should you buy BGM Group stock or one of its competitors? MarketBeat compares BGM Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BGM Group include Aardvark Therapeutics (AARD), Cue Biopharma (CUE), Spero Therapeutics (SPRO), Organigram Global (OGI), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry.

How does BGM Group compare to Aardvark Therapeutics?

BGM Group (NASDAQ:BGM) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Aardvark Therapeutics has a consensus price target of $16.30, suggesting a potential upside of 194.76%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than BGM Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aardvark Therapeutics
2 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.46

BGM Group has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.93, suggesting that its stock price is 293% more volatile than the broader market.

BGM Group's return on equity of 0.00% beat Aardvark Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BGM GroupN/A N/A N/A
Aardvark Therapeutics N/A -61.71%-56.29%

In the previous week, Aardvark Therapeutics had 2 more articles in the media than BGM Group. MarketBeat recorded 4 mentions for Aardvark Therapeutics and 2 mentions for BGM Group. Aardvark Therapeutics' average media sentiment score of 0.84 beat BGM Group's score of 0.30 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BGM Group
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aardvark Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BGM Group has higher revenue and earnings than Aardvark Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BGM Group$25.10M1.07-$1.44MN/AN/A
Aardvark TherapeuticsN/AN/A-$57.59M-$3.21N/A

Summary

Aardvark Therapeutics beats BGM Group on 7 of the 11 factors compared between the two stocks.

How does BGM Group compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and BGM Group (NASDAQ:BGM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

BGM Group has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. BGM Group's return on equity of 0.00% beat Cue Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Cue Biopharma-59.65% -98.30% -53.69%
BGM Group N/A N/A N/A

In the previous week, BGM Group had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 2 mentions for BGM Group and 0 mentions for Cue Biopharma. BGM Group's average media sentiment score of 0.30 beat Cue Biopharma's score of 0.00 indicating that BGM Group is being referred to more favorably in the news media.

Company Overall Sentiment
Cue Biopharma Neutral
BGM Group Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cue Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Cue Biopharma has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market.

BGM Group has lower revenue, but higher earnings than Cue Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cue Biopharma$27.47M4.73-$26.60M-$5.58N/A
BGM Group$25.10M1.07-$1.44MN/AN/A

35.0% of Cue Biopharma shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by insiders. Comparatively, 58.7% of BGM Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

BGM Group beats Cue Biopharma on 7 of the 11 factors compared between the two stocks.

How does BGM Group compare to Spero Therapeutics?

BGM Group (NASDAQ:BGM) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Spero Therapeutics has a net margin of 24.90% compared to BGM Group's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat BGM Group's return on equity.

Company Net Margins Return on Equity Return on Assets
BGM GroupN/A N/A N/A
Spero Therapeutics 24.90%35.58%24.95%

In the previous week, Spero Therapeutics had 8 more articles in the media than BGM Group. MarketBeat recorded 10 mentions for Spero Therapeutics and 2 mentions for BGM Group. Spero Therapeutics' average media sentiment score of 0.43 beat BGM Group's score of 0.30 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BGM Group
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Spero Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Spero Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

BGM Group has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Spero Therapeutics has higher revenue and earnings than BGM Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BGM Group$25.10M1.07-$1.44MN/AN/A
Spero Therapeutics$66.80M1.25$8.57M$0.246.00

25.6% of Spero Therapeutics shares are owned by institutional investors. 58.7% of BGM Group shares are owned by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Spero Therapeutics beats BGM Group on 10 of the 12 factors compared between the two stocks.

How does BGM Group compare to Organigram Global?

Organigram Global (NASDAQ:OGI) and BGM Group (NASDAQ:BGM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

34.6% of Organigram Global shares are held by institutional investors. 0.1% of Organigram Global shares are held by insiders. Comparatively, 58.7% of BGM Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BGM Group has lower revenue, but higher earnings than Organigram Global.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organigram Global$185.07M0.71-$17.70M-$0.13N/A
BGM Group$25.10M1.07-$1.44MN/AN/A

Organigram Global has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organigram Global
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

BGM Group has a net margin of 0.00% compared to Organigram Global's net margin of -9.22%. BGM Group's return on equity of 0.00% beat Organigram Global's return on equity.

Company Net Margins Return on Equity Return on Assets
Organigram Global-9.22% -13.41% -9.09%
BGM Group N/A N/A N/A

In the previous week, Organigram Global had 1 more articles in the media than BGM Group. MarketBeat recorded 3 mentions for Organigram Global and 2 mentions for BGM Group. Organigram Global's average media sentiment score of 0.79 beat BGM Group's score of 0.30 indicating that Organigram Global is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organigram Global
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BGM Group
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

BGM Group beats Organigram Global on 7 of the 13 factors compared between the two stocks.

How does BGM Group compare to enGene?

BGM Group (NASDAQ:BGM) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

BGM Group has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market. Comparatively, enGene has a beta of -0.28, suggesting that its stock price is 128% less volatile than the broader market.

64.2% of enGene shares are held by institutional investors. 58.7% of BGM Group shares are held by insiders. Comparatively, 10.5% of enGene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BGM Group has higher revenue and earnings than enGene.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BGM Group$25.10M1.07-$1.44MN/AN/A
enGeneN/AN/A-$117.30M-$2.17N/A

In the previous week, enGene had 3 more articles in the media than BGM Group. MarketBeat recorded 5 mentions for enGene and 2 mentions for BGM Group. BGM Group's average media sentiment score of 0.30 beat enGene's score of 0.08 indicating that BGM Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BGM Group
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
enGene
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

enGene has a consensus target price of $11.05, suggesting a potential upside of 490.67%. Given enGene's stronger consensus rating and higher possible upside, analysts plainly believe enGene is more favorable than BGM Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
enGene
2 Sell rating(s)
8 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.14

BGM Group's return on equity of 0.00% beat enGene's return on equity.

Company Net Margins Return on Equity Return on Assets
BGM GroupN/A N/A N/A
enGene N/A -56.06%-45.64%

Summary

BGM Group beats enGene on 7 of the 12 factors compared between the two stocks.

Get BGM Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BGM vs. The Competition

Export
MetricBGM GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$27.39M$3.69B$6.89B$12.28B
Dividend YieldN/A2.16%2.67%9.39%
P/E RatioN/A20.4927.1023.94
Price / Sales1.07300.39517.5191.95
Price / CashN/A60.3126.6847.25
Price / Book0.047.9210.666.14
Net Income-$1.44M$23.81M$3.60B$331.74M
7 Day Performance-18.66%-1.27%-1.51%-1.72%
1 Month Performance-24.66%2.56%1.11%-1.44%
1 Year Performance-97.56%42.49%23.77%16.97%

BGM Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BGM
BGM Group
0.8815 of 5 stars		$0.28
-2.4%		N/A-97.5%$27.39M$25.10MN/A298
AARD
Aardvark Therapeutics
3.9454 of 5 stars		$6.26
+5.0%		$19.70
+214.7%		-49.6%$130.43MN/AN/A18
CUE
Cue Biopharma
0.1636 of 5 stars		$31.28
+1.2%		N/A-96.2%$129.88M$27.47MN/A60
SPRO
Spero Therapeutics
1.1337 of 5 stars		$1.70
-22.0%		N/A-33.3%$126.22M$66.80M7.08150
OGI
Organigram Global
1.5329 of 5 stars		$0.89
-0.6%		N/A-37.9%$126.15M$185.07MN/A1,139

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BGM) was last updated on 7/20/2026 by MarketBeat.com Staff.
From Our Partners
Sam Altman backs small company that could save U.S. power grid
A small Colorado company holds the rights to technology that could protect the U.S. public power grid from col...
Altimetry | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...
Monument Traders Alliance | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...
SmartAsset | Sponsoredtc pixel
Trump’s emergency dollar reset
Bloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...
Porter & Company | Sponsoredtc pixel
It’s one of Trump’s biggest holdings. Do you own it?
President Trump holds up to $5 million in shares of an AI company that just landed a nearly $10 billion Pentag...
InvestorPlace | Sponsoredtc pixel